Daytrana Manufacturing Woes Continue With FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Jan. 9 warning letter cites manufacturing deficiencies related to the transdermal ADHD patch.
You may also be interested in...
No Deficit To Shire’s Top Line In ADHD
New product sales drive firm’s revenue growth, including an impressive market grab by attention deficit/hyperactivity disorder product Vyvanse.
No Deficit To Shire’s Top Line In ADHD
New product sales drive firm’s revenue growth, including an impressive market grab by attention deficit/hyperactivity disorder product Vyvanse.
Shire Voluntarily Withdraws Daytrana Patches After Enhancing Adhesive
Firm’s decision comes after patients and caregivers experienced difficulty removing the release liner from some Daytrana patches.